Is tucatinib/tucatinib effective in treating gastric cancer?

Tucatinib/Tucatinib (Tucatinib) is a class of targeted therapy drugs that are tyrosine kinase inhibitors (TKIs). It has been approved for the treatment of patients with HER2-positive advanced breast cancer by targeting and inhibiting the HER2 (human epidermal growth factor receptor 2) signaling pathway. SinceHER2 plays an important role in many types of cancer, including breast cancer, colorectal cancer, etc., tucatinib has proven to have significant clinical efficacy in the treatment of these cancers. However, the efficacy and indications of tucatinib for gastric cancer are still in the clinical research stage, and it has not yet been officially approved as a treatment for gastric cancer.

Gastric cancer is a common malignant tumor of the digestive system with high morbidity and mortality, especially in Asian countries. Although there are many drug options for the treatment of gastric cancer, such as chemotherapy, radiotherapy, immunotherapy and targeted therapy (such as Herceptin, i.e. trastuzumab is used for patients withHER2-positive gastric cancer), for some patients with HER2-positive gastric cancer, the efficacy of existing treatment options is still limited.

Tucatinib is a drug that targets HER2. Its main mechanism of action is to inhibit the activation of HER2 receptors, thereby reducing the proliferation and metastasis of tumor cells. In the treatment of breast cancer, tucatinib has achieved significant clinical effects, especially in some patients who have failed other treatments. Based on this mechanism, the potential of tucatinib in the treatment of gastric cancer has also attracted widespread attention.

Currently, the company developing tucatinibSeagen Inc has launched multiple clinical trials of tucatinib in gastrointestinal malignant tumors. These trials mainly focus on evaluating the therapeutic effect of tucatinib on HER2-positive gastric cancer, colorectal cancer and other diseases. Although preliminary research data suggests that tucatinib may have some efficacy in some patients with HER2-positive gastric cancer, the drug is not currently approved as a standard treatment for gastric cancer.

References:https://www.onclive.com/view/tucatinib-combo-has-potential-as-second-line-option-in-her2-gastric-gej-cancers